← Leaderboards
Paraskevi Giannakakou
Emory University
$12,786,350
Attributed
$17,532,650
Total exposure
11
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.9M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$17,532,650 · 11
By mechanism
R01$13,581,036 · 7
P01$1,695,873 · 1
T32$1,381,859 · 1
P50$473,884 · 1
R21$399,998 · 1
Top collaborators
- Olivier Elemento6 shared
- Manish A Shah6 shared
- John Blenis5 shared
- David S. Rickman5 shared
- Steven P. Balk4 shared
Most similar at Emory University
Same institution · by research overlap
- Joseph Buehler$146,206
- Sharon Ann Swanger$2,353,804
- Hui Mao$16,442,940
Others in their field
Top investigators on “Molecular”
- David Heimbrook · Leidos Biomedical Research, Inc.$871,088,761
- Leonard Freedman · Leidos Biomedical Research, Inc.$468,573,385
- Richard Webby · St. Jude Children'S Research Hospital$254,843,170
- Larry Arthur$238,531,074
- Gregory H Reaman · National Childhood Cancer Foundation$230,630,913
- Ralph Parchment · Leidos Biomedical Research, Inc.$193,231,914
Research focus
MolecularMicrotubulesTaxaneTumorDrug ResistanceChemotherapyCellsBaseResistanceResponseMediatingSamplingProteinsPharmaceutical PreparationsTubulinDocetaxelClinical TrialsCytoskeletonLinkMutationCancer PatientMalignant Neoplasm Of ProstateIn VitroAffect
Grant awards (52)
Enhancing the Efficacy of Docetaxel in Prostate Cancer$654,537
R01 · FY2025 · CA
Enhancing the Efficacy of Docetaxel in Prostate Cancer$621,810
R01 · FY2024 · CA
Enhancing the Efficacy of Docetaxel in Prostate Cancer$641,446
R01 · FY2023 · CA
Enhancing the Efficacy of Docetaxel in Prostate Cancer$672,762
R01 · FY2022 · CA
A novel, short isoform of the +TIP microtubule (MT) binding protein CLIP170 confers taxane resistance by obstructing the MT pore.$501,039
R01 · FY2022 · CA · contact PI
A novel, short isoform of the +TIP microtubule (MT) binding protein CLIP170 confers taxane resistance by obstructing the MT pore.$471,756
R01 · FY2021 · CA · contact PI
Molecular and Translational Oncology Research$285,317
T32 · FY2021 · CA · contact PI
Developmental Research Program (DRP)$97,423
P50 · FY2021 · CA · contact PI
A novel, short isoform of the +TIP microtubule (MT) binding protein CLIP170 confers taxane resistance by obstructing the MT pore.$504,230
R01 · FY2020 · CA · contact PI
Molecular and Translational Oncology Research$259,094
T32 · FY2020 · CA · contact PI
Developmental Research Program (DRP)$93,420
P50 · FY2020 · CA · contact PI
A novel, short isoform of the +TIP microtubule (MT) binding protein CLIP170 confers taxane resistance by obstructing the MT pore$61,478
R01 · FY2020 · CA · contact PI
A novel, short isoform of the +TIP microtubule (MT) binding protein CLIP170 confers taxane resistance by obstructing the MT pore.$489,103
R01 · FY2019 · CA · contact PI
Molecular and Translational Oncology Research$282,993
T32 · FY2019 · CA · contact PI
Biomarkers of taxane chemotherapy response/resistance in prostate cancer$178,800
R21 · FY2019 · CA · contact PI
Developmental Research Program (DRP)$91,453
P50 · FY2019 · CA · contact PI
A novel, short isoform of the +TIP microtubule (MT) binding protein CLIP170 confers taxane resistance by obstructing the MT pore.$504,230
R01 · FY2018 · CA · contact PI
Mechanistic Insights Underlying ERG-induced Taxane Resistance in Castration-Resis$428,881
R01 · FY2018 · CA
Microtubule-Regulated RNA Translation: Implications for Taxane Chemotherapy$337,142
R01 · FY2018 · CA · contact PI
Molecular and Translational Oncology Research$282,148
T32 · FY2018 · CA · contact PI
Biomarkers of taxane chemotherapy response/resistance in prostate cancer$221,198
R21 · FY2018 · CA · contact PI
Developmental Research Program (DRP)$98,339
P50 · FY2018 · CA · contact PI
Mechanistic Insights Underlying ERG-induced Taxane Resistance in Castration-Resis$428,881
R01 · FY2017 · CA
Microtubule-Regulated RNA Translation: Implications for Taxane Chemotherapy$337,142
R01 · FY2017 · CA · contact PI
Molecular and Translational Oncology Research$272,307
T32 · FY2017 · CA · contact PI
Developmental Research Program (DRP)$93,249
P50 · FY2017 · CA · contact PI
Mechanistic Insights Underlying ERG-induced Taxane Resistance in Castration-Resis$428,881
R01 · FY2016 · CA
Microtubule-Regulated RNA Translation: Implications for Taxane Chemotherapy$410,028
R01 · FY2016 · CA · contact PI
Mechanistic Insights Underlying ERG-induced Taxane Resistance in Castration-Resis$428,881
R01 · FY2015 · CA
Microtubule-Regulated RNA Translation: Implications for Taxane Chemotherapy$358,245
R01 · FY2015 · CA · contact PI
Mechanistic Insights Underlying ERG-induced Taxane Resistance in Castration-Resis$428,881
R01 · FY2014 · CA
Microtubule-Regulated RNA Translation: Implications for Taxane Chemotherapy$361,059
R01 · FY2014 · CA · contact PI
Microtubule dependent AR signaling predicts taxane sensitivity$319,746
R01 · FY2013 · CA · contact PI
Microtubule dependent AR signaling predicts taxane sensitivity$340,155
R01 · FY2012 · CA · contact PI
Microtubule dependent AR signaling predicts taxane sensitivity$340,155
R01 · FY2011 · CA · contact PI
Targeting Microtubules and HDAC6 in NSCLC$407,769
P01 · FY2010 · CA · contact PI
Microtubule dependent AR signaling predicts taxane sensitivity$350,675
R01 · FY2010 · CA · contact PI
Targeting Microtubules and HDAC6 in NSCLC$365,353
P01 · FY2009 · CA · contact PI
Microtubule dependent AR signaling predicts taxane sensitivity$350,675
R01 · FY2009 · CA · contact PI
Microtubule-targeting and regulation of HIF-1$283,146
R01 · FY2009 · CA · contact PI
Targeting Microtubules and HDAC6 in NSCLC$354,908
P01 · FY2008 · CA · contact PI
Microtubule-targeting and regulation of HIF-1$283,146
R01 · FY2008 · CA · contact PI
Targeting Microtubules and HDAC6 in NSCLC$351,592
P01 · FY2007 · CA · contact PI
Antitubulin drugs: Mechanisms of action and resistance$283,544
R01 · FY2007 · CA · contact PI
Microtubule-targeting and regulation of HIF-1$283,146
R01 · FY2007 · CA · contact PI
Antitubulin drugs: Mechanisms of action and resistance$292,013
R01 · FY2006 · CA · contact PI
Microtubule-targeting and regulation of HIF-1$291,603
R01 · FY2006 · CA · contact PI
Targeting Microtubules and HDAC6 in NSCLC$216,251
P01 · FY2006 · CA · contact PI
Microtubule-targeting and regulation of HIF-1$280,940
R01 · FY2005 · CA
Antitubulin drugs: Mechanisms of action and resistance$270,560
R01 · FY2005 · CA
Antitubulin drugs: Mechanisms of action and resistance$270,560
R01 · FY2004 · CA
Antitubulin drugs: Mechanisms of action and resistance$270,560
R01 · FY2003 · CA